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1  |  INTRODUC TION
Primary hypothyroidism affects about 3% of the general popula-
tion in Europe.1 The majority of people are treated adequately with 
levothyroxine (L- thyroxine). However, 5%– 10% of treated hypothy-
roid patients report impaired quality of life, despite achieving free T4 
and thyroid- stimulating hormone (TSH) levels within the laboratory 
reference range.2 A proportion of patients with hypothyroidism, 
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Introduction: Recent prescribing policies in England and Wales have imposed signifi-
cant restrictions on liothyronine prescribing in general practice driven by the prohibi-
tive costs and uncertain benefits of liothyronine in the management of hypothyroidism. 
However, the impact of these policies on liothyronine usage and costs is still unclear.
Methods: Data were downloaded from the NHS monthly General Practice Prescribing 
Data in England and from the Comparative Analysis System for Prescribing Audit 
(CASPA) in Wales for 2011– 2020. Trends over the period in amount and costs of levo-
thyroxine and liothyronine prescribing were analysed.
Results: The total medication costs per year for England Wales for hypothyroidism 
rose from £60.8 million to £129.8 million in 2015– 16 and have since reduced to £88.4 
million. Levothyroxine prescriptions have been growing above the population growth 
rate at 0.7%/annum in England and 1.1% in Wales. The costs/patient/year for liothy-
ronine rose from £550 to £3000 in 2015– 16 and has since fallen to £2500. Use of 
liothyronine as a percentage of levothyroxine started to fall in 2015– 16 at 7%/annum 
in England and 3% in Wales. Nevertheless, 0.5% of levothyroxine- treated patients 
continue to receive liothyronine. All Clinical Commission Groups (CCGs) in England 
continue to have at least one liothyronine prescribing practice and 48.5% of English 
general practices prescribed liothyronine in 2019– 20.
Conclusion: In spite of strenuous attempts to limit prescribing of liothyronine in gen-
eral practice, a significant number of patients continue to receive this therapy. The 
price differential of liothyronine vs levothyroxine should be examined again in light of 
the continuing use of liothyronine.
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including those who continue to feel unwell on Levothyroxine, are 
prescribed liothyronine (L- tri- iodothyronine), usually in addition to 
levothyroxine.2
Liothyronine/levothyroxine combination therapy was originally 
widely prescribed when synthetic thyroid hormones first replaced 
animal thyroid extracts. However, with its more favourable pharma-
cokinetics allowing for once daily dosing, and equivocal evidence for 
any additional benefit of liothyronine, levothyroxine monotherapy 
has prevailed as the treatment of choice for primary hypothyroidism. 
However, early studies were small, used somewhat higher doses of 
liothyronine than used in clinical practice, and resulted in adverse 
symptoms consistent with thyrotoxicosis.3 Subsequent more recent 
trials failed to show convincing benefit for combined thyroid hor-
mone replacement and thus clinical guidelines advise against the 
routine prescribing of liothyronine.4– 6
The European Thyroid Association recommends that liothy-
ronine/levothyroxine combination therapy might be considered as 
an experimental approach in hypothyroidism for patients who are 
adherent to levothyroxine yet experience persistent symptoms de-
spite serum TSH values within the reference range.4 The American 
Thyroid Association notes that there is currently insufficient evi-
dence to support the routine use of combination therapy outside 
a formal clinical or N- of- 1 trial5; and largely based on these guide-
lines, the British Thyroid Association recommends that liothyronine/
levothyroxine combination therapy may only be considered by en-
docrinologists for patients who have unambiguously not benefited 
from levothyroxine.6
More recently in the United Kingdom (UK), the use of liothy-
ronine has been further discouraged because of significant price 
inflation due to monopoly status of the generic supplier since it was 
debranded in 2007. The current price in 2020 of 28 tablets of 20 μg 
liothyronine is £165.18, compared with £26.15 in 2010 thus increas-
ing by a factor of more than six.7 This has resulted in NHS England 
listing liothyronine as a medicine that should not be prescribed rou-
tinely in primary care,8 although it is still licensed. In Wales, liothy-
ronine is categorized as a ‘low priority for funding’ medicine, and 
may not be prescribed routinely for patients who are not under the 
care of an endocrinologist.9
A small amount of natural desiccated thyroid (NDT) is prescribed 
by general practitioners and a few endocrinologists; because NDT 
has been around for so long, it did not ever need to go through the li-
censing process in the USA— it was classed as a ‘grandfathered drug’. 
It has always been approved by the Food and Drug Administration 
(FDA) but not licensed in the same way that many other drugs have 
been. In the UK, it is licensed for prescription on a named patient 
basis. Both liothyronine and NDT are available in the UK through 
NHS and Private prescriptions issued by endocrinologists and gen-
eral practitioners and are prescribed broadly in accordance with na-
tional guidance.6 Supplies of NDT prescribed in the UK come from 
licensed manufacturers in the USA and Canada (Armour Thyroid 
only).
It should be pointed out that NDT is not regulated in the same 
way in the UK as fully licensed preparations. Furthermore, NDT 
which is derived from porcine thyroid gland contains both levothy-
roxine and liothyronine, but the balance of levothyroxine and lio-
thyronine in NDT preparations is not the same as in humans, with a 
greater proportion of liothyronine which may increase risk of over- 
treatment and suppression of TSH.10
The aim of the study presented here was to compare the changes 
in liothyronine and levothyroxine prescribing in England and Wales 
over the period 2011– 12 to 2019– 20.
2  |  METHODS
2.1  |  Data sources
The NHS in England and Wales both publish details of prescrip-
tions issued in primary care. In England, monthly prescribing data 
were obtained from NHS Business Service Authority, who pub-
lish practice- level prescribing information for all general practices 
including the total number of items prescribed and dispensed.7 In 
Wales, data were extracted from the Comparative Analysis System 
for Prescribing Audit (CASPA, CASPA.net) which contains compara-
ble information on items and cost to the NHS, and prescribing data 
as in England.11 The English data are publically available, while the 
What we knew
Increased blood testing in recent years has identified more 
patients with hypothyroidism and use of levothyroxine 
has increased. However, 5%– 10% of levothyroxine users 
continue to experience profound and sometimes disabling 
symptoms, such as fatigue, depression and impaired cogni-
tion, in spite of being adherent to levothyroxine and seem-
ingly adequately replaced from a biochemical point of view.
Historically, some have been using liothyronine as an ad-
junct therapy, but questions over the benefits of liothyro-
nine have resulted in existing patients being encouraged to 
switch back to mono therapy with levothyroxine.
What we have learnt
Levothyroxine prescribing has increased over the last years 
in Wales and in England, but in spite of strenuous attempts 
to limit prescribing of liothyronine in general practice, a 
significant number of doctors still prescribe liothyronine 
across all geographical areas.
Given how common hypothyroidism is, adequately pow-
ered clinical trials of liothyronine/ levothyroxine replace-
ment are still urgently needed.
The price ratio of liothyronine to levothyroxine is very dif-
ferent in the United Kingdom than in the rest of Europe 
and should be examined again, given that this combination 
continues to be prescribed widely.
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Welsh data are provided free to NHS users, general practitioners 
and Health Boards.12 The database includes as above a basic price 
for levothyroxine and liothyronine, evaluated at national level from 
2011– 12 to 2019– 20, a period of 9 years.
2.2  |  Database analysis
For each medicine, we took the total quantity of medicine pre-
scribed by dose and British National Formulary (BNF) code. 
Defined daily dose (DDD) was used to quantify medication doses. 
DDD is a standard method of comparing doses of a given medica-
tion and is taken as the average maintenance dose per day of a 
drug administered for its main indication in adults.13 The amount 
of active agent was converted to defined daily doses by applying 
the levels given in the World Health Organisation and Anatomical 
Therapeutic Chemical (WHO/ATC) classification. For liothyro-
nine which is most often used in combination with levothyrox-
ine, an adjusted dose of 20 mcg/day was applied. In England, 
the ‘Actual Cost’ included adjustments for the national average 
discount and payments to dispensers. In Wales, the ‘Basic Cost’ 
was used.
TA B L E  1  England 2019– 20 Prescribing for Hypothyroidism in Primary Care
BNF chemical Mcg
Number of 





Levothyroxine (T4) (DDD = 150 mcg) 100 7580 11,654,496 £20,523,845 798,866 £26
50 7598 10,622,081 £19,329,359 350,343 £55
25 7604 10,358,911 £23,189,455 174,688 £133
75 6799 751,146 £2,254,374 34,530 £65
12.5 3229 56,387 £162,859 441 £369
125 143 347 £73,850 110 £673
250 3 26 £8690 21 £414
150 5 15 £7000 3 £2777
200 1 3 £884 1 £896
175 1 1 £358 0 £1867
T4 Sub- Total 7830 33,443,413 £65,550,674 1,359,002 £48
Liothyronine (T3) (DDD = 20 mcg) 20 3068 50,297 £14,603,286 6483 £2252
5 662 3843 £1,420,942 258 £5514
10 96 213 £72,780 15 £4967
2.5 30 192 £82,663 7 £12,612
25 51 178 £52,879 40 £1309
50 3 3 £959 2 £522
Sub- Total 3238 54,726 £16,233,509 6,804 £2386
Natural Desiccated Thyroid (NDT) 
(DDD = 120 mg)
60 232 1358 £470,812 219 £2145
30 141 720 £239,847 66 £3635
120 70 251 £110,914 72 £1532
15 48 204 £67,289 7 £9285
90 39 145 £48,791 28 £1772
66 18 88 £26,545 17 £1570
65 17 59 £17,817 11 £1558
32.5 12 48 £20,466 5 £3858
125 5 10 £3650 3 £1383
132 4 9 £2339 3 £918
130 4 8 £2954 2 £1244
33 2 6 £886 0 £1961
100 1 5 £646 1 £1011
180 1 1 £399 1 £694
NDT Sub- Total 382 2912 £1,013,356 436 £2327
Grand Total 7831 33,501,051 £82,797,539 1,366,242 £61
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2.3  |  Data analysis
Annual trends in drug volumes, unit prices and numbers on treat-
ment were plotted as counts or costs in British pound sterling. We 
calibrated prescribing of thyroid hormone replacement against the 
number of women in each general practice older than 25 years. In 
other words, the number of prescriptions as DDD was normalized 
for comparison between general practices by the number of women 
aged over 25 years old.14 The gender and age mix for each practice 
was taken from the population data at general practice level.11 All 
the data used in the analyses presented are publicly available and 
can be made appropriately available on request from MS, co- author.
3  |  RESULTS
3.1  |  Current prescribing ENGLAND 2019– 20
In England, 1.36 million people on the full year basis were on levo-
thyroxine therapy and the most common tablet strengths prescribed 
were 100 mcg, 50 mcg and 25 mcg tablets (Table 1). Approximately 
0.5% (n = 6804) of hypothyroid individuals were on T3, nearly all in 
combination with levothyroxine, and mostly at a dose of 20 mcg/day. 
Only 436 people were recorded as prescribed natural desiccated 
thyroid (NDT). The average cost of liothyronine per patient year was 
£2386 which was equivalent to 50 times the cost of levothyroxine 
at £48 per patient year.
3.2  |  Current prescribing WALES 2019– 20
In Wales, 88,000 people on a full year basis were on levothyrox-
ine therapy with 3 tablet strengths most commonly prescribed 
(100 mcg/50 mcg/25 mcg tablets). 315 individuals equivalent to 
about 0.45% of hypothyroid individuals were on liothyronine, 
mostly in combination with levothyroxine and mostly at 20 mcg/
day, similar to England (Table 2). 36 people were recorded as 
prescribed NDT. The average cost of liothyronine per patient 
year was £2729 which was approximately 57 times the cost of 
levothyroxine per patient per year at £53. Thus, the ratio of 
liothyronine to levothyroxine cost was marginally higher than in 
England.
TA B L E  2  Wales 2019– 20 prescribing for hypothyroidism in primary care
Type Amount mcg
Number 





Levothyroxine (DDD = 150 mcg) 100 439 896,013 £1,496,216 52,541 £28
50 434 810,819 £1,433,113 22,508 £64
25 435 783,651 £1,573,303 10,976 £143
75 391 49,636 £134,362 1932 £70
12.5 189 5033 £13,853 36 £387
125 9 21 £4000 6 £626
250 1 3 £1398 2 £680
T4 Total 443 2,545,176 £4,656,246 88,001 £53
Liothyronine (DDD = 20 mcg) 20 168 2364 £691,184 285 £2426
5 41 408 £152,581 25 £6048
25 4 20 £5086 3 £1954
2.5 2 16 £5454 0 £11,849
10 1 10 £5313 1 £4618
50 1 1 £545 1 £663
T3 Total 190 2819 £860,163 315 £2729
Natural Desiccated Thyroid (NDT) 
(DDD = 120 mg)
60 28 144 £66,659 27 £2463
30 10 79 £24,021 6 £4354
15 3 28 £3261 0 £8442
125 2 7 £1805 2 £798
120 1 3 £759 1 £923
32.5 2 3 £122 0 £891
65 1 1 £12 0 £1004
NDT Total 31 265 £96,639 36 £2669
Grand Total 444 2,548,260 £5,613,047 88,353 £64
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3.3  |  Trends over time in prescribing and cost
In England (Figure 1A), the number of individuals on levothyroxine 
therapy rose from 1.15 million to 1.36 million and is still growing at a 
rate of 3.4% per year (Figure 1A). The annual spend on hypothyroid-
ism peaked in 2016– 17 at £122 million per year of which 25% was 
spent on liothyronine (£30 million). The current spend is now around 
£83 million with 21% spent on liothyronine (£16 million).
In Wales (Figure 1B), the numbers of individuals on levothyrox-
ine rose from 79,000 to 88,000 and is growing at a rate of 1.4% per 
year. Annual spend has fallen from a peak in 2015– 16 of £8 million 
per year of which 12% was the cost of liothyronine prescriptions 
(Figure 1B). The current total basic price is £5.6 million with 15.4% 
liothyronine (£860,000). Overall, the trends were similar to England.
3.4  |  Changes in levels of use and unit costs across 
time England and Wales
There has been a growth in the percentage being treated for hypo-
thyroidism as measured as percentage of women in both England 
which is lower and growing faster (6.1% to 6.7%) and Wales which 
is higher but growing more slowly (7.2% to 7.6%) (Figure 2A). The 
growth in prescribing of levothyroxine has been steady in both na-
tions over the period examined, although at different rates. The total 
costs of hypothyroidism treatment per patient are similar in both 
countries and overall have risen in the last 8 years due to the cost 
of liothyronine with some reduction more recently since early 2017 
(Figure 2A).
In England, there was a decline in numbers prescribed liothy-
ronine following the 450% price increase 2013– 2016. The price 
increase for liothyronine has now reversed by 30% from £3202 to 
£2390 per annualized DDD per year but it remains 4 times 2012 
levels (Figure 2B). Use of liothyronine in the hypothyroidism cohort 
has only dropped from 0.92% to 0.53% with 57% continuing to use 
this therapy in spite of the price increase. In Wales, the numbers on 
liothyronine grew before 2014 at 6% per year up to 386 individuals. 
The price increased by a factor of 550% from £642/year to £3521/
year. Since 2014– 15, the number on liothyronine has been declining 
by 5% per year to 310 currently. The price of liothyronine has now 
decreased by 23% to £2728/year. And overall use has declined from 
0.51% to 0.4% so 75% continuing to use this therapy in spite of the 
price increase.
In England (Figure 2B), 0.92% of individuals on thyroid hormone 
replacement were on liothyronine in 2011– 12 and that has fallen by 
40% to 0.53% by 2019– 20. In Wales, a smaller percentage (0.46%) 
were on liothyronine therapy at the start of the period but prescrib-
ing volume fell by only 15% to 0.40% at the end of the period. The 
costs of liothyronine were the same in both nations in 2011– 12 
but have diverged, with costs in Wales now being 10% higher than 
England (£2722 Wales vs. £2386/year England).
There was 20% more treatment for hypothyroidism in Wales 
than in England and growth in annual amount prescribed was 5% in 
Wales compared to 10% in England. The average spend per person 
was similar.
3.5  |  Variation in prescribing by CCG in England in 
2019/20
In England, there are 135 local clinical commissioning groups of 
different sizes. There was significant variation across CCGs in lio-
thyronine prescribing with much less variation in prescribing of levo-
thyroxine (Figure 3). All clinical commissioning groups (CCGs) had 
at least one liothyronine prescribing practice, with 51.5% of general 
practices not prescribing any liothyronine.
There was some variation in the identification and treatment 
of hypothyroidism (with levothyroxine) across different CCGs, and 
the median is 7% of the population of women age > 30. The low-
est decile region is 5.5% and the highest decile is 8.3% of women 
>30 years old. Variation in use of liothyronine is higher. The median 
is 0.4% of those being treated with Levothyroxine. The lowest decile 
is 0.1% and highest decile 0.9% of those treated with levothyroxine.
4  |  DISCUSSION
This data highlight the ongoing rise in levothyroxine prescribing in 
England and Wales. The total number of individuals on Levothyroxine 
increased by a rate of 3% and 1.5% per annum in England and Wales, 
respectively. This is likely multifactorial, reflecting an ageing popula-
tion and widespread use of thyroid function tests. Previous studies 
have shown a steady fall in TSH threshold at initiation of levothyrox-
ine,15 but it is unclear whether this has continued. In contrast, there 
was a relative decline in liothyronine prescribing following a peak 
from about 2015– 2017.
No new major trials of liothyronine have been performed in re-
cent years, indicating that the changes we have observed are eco-
nomically driven rather than clinically driven. Guidance has generally 
been equivocal or has actively discouraged liothyronine prescrib-
ing.4– 6,9 There was a greater decrease in liothyronine prescribing in 
England than in Wales where the price has remained lower, albeit net 
increased since 2011.
In spite of strenuous attempts to limit prescribing of liothyronine 
in general practice, our findings show that a significant number of 
doctors continue to prescribe liothyronine. In England, priorities for 
primary care are set by the local clinical commissioning groups of 
which there are 135 of different sizes. Notably, all CCGs had at least 
one liothyronine prescribing practice suggesting a continued need 
for this treatment whether driven by patients or their clinicians. This 
is in the context of various sets of guidance published in the last de-
cade4– 6,9 which have largely left open the possibility of liothyronine 
being legitimately prescribed. The pattern of prescribing of liothy-
ronine in Wales would also support this.
We have seen a steady increase in levothyroxine prescribing 
over the last 8 years which may relate to the increased number of 
    |  985STEDMAN ET Al.
F I G U R E  1  Annual trends in thyroid hormone replacement prescribing 2011– 12 to 2019– 20 for (A) England and (B) Wales. The bars 
represent the relative total costs of levothyroxine and liothyronine. The black line describes the volume of prescribing of levothyroxine as 
converted to total annualized patients at 150 mcg/day. The orange colour represents annual cost of liothyronine and the blue colour the 
annual cost of levothyroxine [Colour figure can be viewed at wileyonlinelibrary.com]
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F I G U R E  2  Relative growth in number of individuals treated and cost of treatment for (A) hypothyroidism in England and Wales and (B) 
Use of Liothyronine and NDT over the period 2011– 12 to 2019– 20 [Colour figure can be viewed at wileyonlinelibrary.com]
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older people in the population of England and Wales in that pe-
riod,14 while also being a consequence of prescription of levothy-
roxine in people with borderline hypothyroidism.15 We found a 
difference between England and Wales with much less of a de-
crease in liothyronine prescriptions in Wales over recent years. 
Given the significantly smaller size of the population served by 
the National Health Service (NHS) in Wales, a factor in Wales 
may be the influence of local opinion leaders who support pre-
scription of liothyronine in combination with levothyroxine where 
appropriate.
It is possible that the reduction in prescribing of liothyronine, 
captured in the data here, may be missing patients discontinuing 
NHS prescriptions but choosing to obtain ongoing private prescrip-
tions or non- prescription sources of liothyronine and of NDT; this 
cannot be captured in this sort of analysis.
NHS data reflecting a reduction in non- conventional prescrib-
ing may therefore be missing a cohort of patients seeking private 
liothyronine and NDT who may not be being monitored for safety 
or harm. Whilst this hidden group may not be possible to quantify, 
it should be noted that they are likely to exist and current prescrib-
ing pattern changes may lead to an increase in this disenfranchised 
group of patients who may be inadequately treated and monitored 
and who may come to harm from this change in NHS prescribing 
patterns.
4.1  |  Cost
Levothyroxine is on the World Health Organization's List of Essential 
Medicines, that is, the safest and most effective medicines needed 
in a health system. The wholesale cost in the developing world is 
about £0.43 (US$0.58) (bb) to £9.20 (US$12.28) per month.15 In the 
United States, a typical month of treatment costs less than US$25 
(£18.72). Levothyroxine was the third most commonly prescribed 
medication in the United States in 2017, with more than 101 million 
prescriptions issued per year.
Liothyronine is available as a generic medication. A month's sup-
ply in the United Kingdom costs the NHS about GB £247 (US$330) 
as of 2019. In the United States, the wholesale cost of this amount is 
about US$22.40 (£16.80). In 2017, liothyronine was the 252nd most 
commonly prescribed medication in the United States, with more 
than one million prescriptions per year.16
Taylor et al17 similarly looked at prescribing of liothyronine over time 
in England and noted that the change in prescribing was largely driven 
by cost. They showed that between August, 2013, and July, 2018, there 
was a median 37% reduction in the ratio of liothyronine prescriptions 
per 1000 levothyroxine prescriptions nationwide, with a maximum 
32- times reduction in one CCG. Analysis of CCG demographics in that 
study showed that for that for each quintile increase in economic depri-
vation, liothyronine prescriptions were 0.21 standard deviations lower.
F I G U R E  3  Percentage of levothyroxine and liothyronine prescribing across for all CCGs in England (Ranked by Deciles) [Colour figure can 
be viewed at wileyonlinelibrary.com]
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Judgements on the cost- effectiveness of liothyronine in the UK 
appear to be made implicitly in policy guidelines, driven in large part 
by the significant difference in the current unit acquisition cost be-
tween liothyronine and levothyroxine. Guidelines either consider li-
othyronine/levothyroxine combination therapy to be non- inferior to 
levothyroxine alone (based on the available weak clinical evidence), 
or to be inferior because of the shorter pharmacokinetic elimination 
half- life and safety concerns. Neither perspective is fully justifiable, 
as the current evidence base is not targeted to the specific popula-
tion in question, and inferiority has not been demonstrated. Pending 
further studies to clarify the role of combination therapy, patients 
who derive symptomatic benefit from it should not be deprived of 
treatment for economic reasons alone.
It has been stated that 5%– 10% of people with hypothyroidism 
may be unresponsive to levothyroxine.2 However, only a small pro-
portion of these are currently receiving liothyronine. At present, it 
remains to be seen what proportion of these will benefit from li-
othyronine either in its current form or in the form of newer lon-
ger acting preparations currently under development. Certainly, 
recent evidence has shown that a small but significant proportion 
of people treated for hypothyroidism remain actively symptom-
atic.18,19 Interestingly, it is noteworthy that even in the 1970s it was 
recognized that some patients did not feel well on levothyroxine 
monotherapy and seemed to prefer liothyronine being used in com-
bination with levothyroxine.20
Decisions concerning the formulary restriction, deprescribing or 
disinvestment in liothyronine prescribing ought to consider the po-
tential implications, which are both clinical and economic, and specific 
to individual patients. Perhaps, now is the time for the NHS to con-
sider negotiating with the liothyronine suppliers given the very low 
cost of this drug in other countries (eg, in Australia the cost for 100 
tablets of 20 microgram strength is only AUD$69 or £38 pound.21
4.2  |  Quality of life implications
Most guidance documents advocate a 3- month trial period, as mod-
elled in the current analysis, when initiating liothyronine in eligible 
populations. Deprescribing may be appropriate on a case- by- case 
basis, and with patient agreement.19 However, there is no pub-
lished analysis on quality of life and other health- related outcomes 
when liothyronine is stopped. Finally, some general practitioners 
prescribing liothyronine may be doing so after an endocrinologist 
has assessed the patient and recommended the use of liothyronine 
with levothyroxine in keeping with the British, European and US 
guidelines.4– 6
4.3  |  Strengths/Limitations
While we have not looked at data from Scotland and Northern 
Ireland, there is no reason to suspect that the findings here would 
not be applicable to the other parts of the UK, albeit that the NHS 
is organized differently in each of the other two nations. Also we 
have not here looked specifically at the prescribing of NDT at gen-
eral practice level nor in trends of prescribing over time. This will 
be the subject of a further paper. Finally, we were not able to look 
specifically at prescribing of liothyronine alone.
5  |  CONCLUSION
Levothyroxine prescribing has increased but in spite of strenuous 
attempts to limit prescribing of liothyronine in general practice, a 
significant number of doctors/patients still feel that this treatment is 
beneficial in Wales and in England. Given how common hypothyroid-
ism is, adequately powered clinical trials of liothyronine/ levothyrox-
ine replacement are still urgently needed.
The price differential of liothyronine vs levothyroxine should be 
examined again, given that a proportion of both clinicians and pa-
tients perceive benefit in combination treatment.
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